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Abstract 
Purpose: To assess the knowledge and attitudes of physicians towards adverse drug reaction (ADR) 
reporting at King Khalid University Hospital, Riyadh, Saudi Arabia. 
Method: The study was conducted in King Khalid University Hospital (KKUH), Riyadh, Saudi Arabia 
over a three-month period (April to June 2014). A self-administered questionnaire was delivered to 116 
physicians. The questionnaire comprised of close-ended as well as open-ended questions. Descriptive 
statistics including, frequency distribution and percentages, were used for both demographic data and 
various responses to the questions. 
Results: The response rate was 81.09 %. The mean age of the respondents was 33.3 ± 11.49 years. 
Of the 94 physicians who completed the questionnaire, 88.7 % of them didn’t know about the National 
Pharmacovigilance Center. Almost all the physicians (95.7 %) were not satisfied by their training in 
ADRs reporting while half (49.3 %) of the respondents thought that only serious ADRs should be 
reported. 
Conclusion: There is a need for more educational and training programs for physicians regarding the 
pharmacovigilance system and ADRs reporting. More research is needed to study the knowledge and 
attitudes of other healthcare professionals and in various settings. 
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In 1969, the WHO [1] defined Adverse Drug 
Reactions (ADRs) as any noxious unintended 
reaction to a drug which occur at normal doses 
used in the prophylaxis, diagnosis or the 
treatment of diseases. However, according to the 
International Conference on Harmonisation ICH 
guidelines 1996, adverse drug reactions (ADRs) 
are any harmful unintended response to a drug 
regardless of the dose [2].  
 
ADRs is a worldwide healthcare problem, in the 
US several studies have estimated the incidence 
of ADRs in hospitalized patients ranged from 5.2 
- 8.2 %, and around 5 % of these incidences 
resulted in death [3]. The estimated annual cost 
of adverse drug events (ADE) including ADRs in 
the US is between 30 billion to 130 billion dollars 
[ 4 ], this figure accounts only for direct costs of 
ADRs like increased hospitalization, ER visits 
and physician visits and does not take into 
account the indirect costs (i.e., decrease in 
productivity). In France, an epidemiological study 
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of 2067 adults visiting healthcare centers found 
that 14.7 % of them suffered from adverse drug 
reactions [5] while in the UK, it was estimated  
that 6.8 % of hospital admissions were related to 
ADRs with a projected annual cost of 847 million 
dollars [6].  
 
In Saudi Arabia, data are still limited, however, in 
a prospective study the incidence of non-
preventable ADE in a sample of patients 
admitted to a teaching hospital over 4 months 
was 6 %; with oral anticoagulants as the most 
frequently implicated drug class[7] . In the same 
teaching hospital (King Khalid University 
Hospital) a retrospective study found that 54 % of 
ADRs were of type A and 39 % of type B [8]. 
There is a possibility that ADRs are greatly 
underreported in Saudi hospitals; in two studies it 
was found that after the implementation of an 
intensive pharmacovigilance monitoring program 
for six months in two departments in a university 
hospital in the western region of Saudi Arabia, 
ADRs incidence rate detected has risen from 4.5 
and 3.1 % the year before the program 
implementation to 8.2 and 5.1 %, respectively, 
detected during the program [9,10] .  
 
The aim of this study was to assess the 
knowledge and experience of physicians with 
ADRs reporting and to identify potential factors 
that may encourage or discourage physicians 






This study used a cross sectional design to 
evaluate the knowledge, attitude and perception 
about ADRs among physicians.  A total of 116 
questionnaires were distributed to physicians by 
convenience sampling techniques. Copies of the 
questionnaire were handled to participants either 
by hand or via the departments’ secretaries.  
 
Subjects and setting 
 
King Khalid University Hospital (KKUH) is the 
major teaching hospital of the College of 
Medicine, King Saud University, in Riyadh. It is 
one of the largest secondary and tertiary care 
centers in the area, with a capacity of 800 beds. 
Study participants were physicians working in 
King Khalid University Hospital (KKUH). The data 
were collected from April to June 2014 using self-
administered questionnaire. This study was 
granted ethical approval by the college of 





The questionnaire consisted of two sections; the 
first section compiled demographic information 
and the second segment consisted of 27 
questions. Some questions were close-ended 
and others open-ended. The questionnaire was 
distributed in both electronic and paper formats 
to 116 physicians for self-completion. All the 
paper formats were filled on the spot while those 
sent electronically were given 2 weeks complete 
and return, and a single reminder was sent 1 




The data from each of the returned questionnaire 
were coded and entered into Statistical Package 
for the Social Sciences (SPSS) version 21 
software (SPSS Inc, Chicago, IL, USA) which 
was used for statistical analysis. Accuracy of 
data entry was assessed by independent, 
random checking of 10 % of the sample; missing 
data and blank cells were examined against the 
original data to identify any discrepancies. 
Descriptive statistics, including frequency 
distribution and percentages, were applied to 





Ninety-four questionnaires were collected giving 
a response rate of 81.09 %. After the exclusion 
of 22 questionnaires due to missing demographic 
information, 72 questionnaires remained for 
statistical analysis. The demographic charac-
teristics of the respondents are summarized in 
Table 1. The mean age of the respondents was 
33.3 ± 11.49 years. Majority of survey 
respondents (54.8 %) have less than 5 years of 
experience. General physicians constituted the 
largest proportion of respondents (43.8 %). Male 
respondents are 64.4% while female 
respondents are only 35.6 %. 
 
Knowledge and reporting of ADRs  
 
Regarding the awareness of ADRs, 63 (87.5 %) 
of respondents were aware that not all drugs 
available in the market were safe and 56 (77.8 
%) experienced ADRs in patients during their 
practice. When asked “How many percent of 
your patients complain about ADRs?” out of 64 
participants who answered this question, 54 
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(96.9 %) of them thought that ≤ 20 % of their 
patients complained about ADRs.  
 
Table 1: Demographic information of physicians 
 
Variable Frequency % 











0 – 4 years 
5 – 9 years 
10 – 14 years 
15 – 20 years 






































The majority (n = 60, 87 %) of respondents said 
that ADRs should be reported by physicians and 
the Head Department of the institute was the 
most chosen option for reporting ADRs (n = 22, 
35.5 %). More than two-thirds (n = 48, 67.6 %) of 
respondents said that they will report any ADR 
whether it is serious, severe or just a mild ADR 
which cause less inconvenience. However, only 
9 (12.9 %) of respondents recognized a nearby 
ADR reporting and monitoring system or center. 
Only 11.3 % (n = 8) and 18.1 (n = 13) knew 
about the pharmacovigilance program of the 
SFDA and conceived any difference in 
awareness of ADR reporting impacted by this 
system, respectively. 
 
Barriers and factors in ADRs reporting 
 
When asked “Do you think that pharmacist could 
be the right person to assist physician in ADR 
reporting”, 61 (85.9 %) of respondent physicians 
replied affirmatively. There was a general 
agreement (n = 69, 97.2 %) among respondents 
that ADR reporting and monitoring will benefit 
patients and the majority (n = 55, 77.5 %) of 
them appreciated the contribution of information 
technologies (i.e. the internet, mobile services) in 
facilitating ADRs reporting. Most of respondents 
(n = 60, 84.5 %) agreed that ADRs reporting 
should be made mandatory.  
 
However, 29 (41.4 %) of respondents didn’t know 
if there were ADR reporting forms available and 
22 (31.4 %) answered “No”. There was a large 
dissatisfaction (n = 41, 58.6 %) by the provided 
ADR information and although 62 (87.3 %) were 
looking forward to be trained in ADR reporting 
there was a larger dissatisfaction (n = 67, 95.7 
%) by the training in ADR reporting. 33 (46.5 %) 
of respondents were worried about legal issues 
when writing ADR reports. When asked about 
the causes of under-reporting of ADRs, the most 
common reasons chosen by physicians were: 
“Don’t know whom to report” (n = 32, 47.8 %), 
“busy schedule” (n = 25, 37.3 %) and “difficult to 
pin point suspected drug” (n = 22, 32.8 %) (Table 
2) .However, although “busy schedule” was 
mentioned by many physician as a reason for 
under-reporting, only 14 (20 %) of them felt that 
ADR reporting is time consuming activity with no 
outcome and 58 % (n = 40) didn’t support “Direct 
ADR Reporting” by the patients instead of 
physicians. 
 
Table 2: Reasons cited by physicians for under-
reporting of ADRs 
 
Reason N (%) 
Don’t whom to report 32 (47.8) 
Busy schedule 25 (37.3) 
Difficult to pin point suspected drug 22 (32.8) 
Thinking one report doesn’t make a 
difference 
21 (31.3) 
Insufficient clinical knowledge 20 (29.9) 
Lack of incentives. 15 (22.4) 
Physicians should rather collect data 
and publish himself/herself. 
12 (17.9) 
Reporting does not influence the 
treatment scheme. 
11 (16.4) 
ADR is known to physicians. 11 (16.4) 
Only safe drugs are available on the 
market. 
8 (11.9) 
Reporting could show ignorance. 8 (11.9) 
Difficult to admit harm to the patient. 6 (9.0) 
Other reasons. 1 (1.5) 
 
Experience with ADRs reporting 
 
Regarding which classes of drugs physicians 
frequently experienced ADRs with, Antibiotics 
(not specified) were the most mentioned class of 
drugs (n = 13, 37.1 %) with additional 8.6 % (n = 
3) of physicians specified vancomycin, 4 (11.4 
%) mentioned steroids and 3 (8.6 %) for both 
statins and non-steroidal anti-inflammatory 
drugs. Only 34 (47.2 %) of participants answered 
the question “What are the sources of ADR 
information to you?”, however, out of them 21 
(61.8 %) mentioned the internet as a source 
compared to 14 (29.8 %), 6 (17.6 %) and 1 (2.9 
%) for hard-copy literature, Drug information 
Center and clinical pharmacist respectively. 
When asked “Which types of ADRs are usually 
reported” 49.3 % of respondents (n = 35) said 
that “serious, unexpected and suspected” only 
should be reported which is more than the 35.2 
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% (n = 25) of participants who said that all of the 
listed types of ADRs should be reported (Table 
3). Most of physicians (n = 55, 77.5 %) agreed 
that patient confidentiality should be maintained 
in the process of ADRs reporting. 77.5 % of 
participants (n = 55) expected feedback from 
ADR monitoring centers. 
 
Table 3: Types of ADR often reported  
 
ADR N (%) 
Serious unexpected and 
suspected  
35 (37.60) 
Any ADR of old drug  4 (4.30) 
Any adverse event  9 (9.70) 
ADR to a new product  10 (10.80) 
Only proven ADRs 3 (3.20) 
All of the above  25 (26.90) 




ADRs monitoring is an area of pharmaceutical 
care which deals mainly with the detection, 
management and reporting of ADRs of drugs 
which may result from drugs that is taken in 
normal dose for prophylaxis, prevention or 
treatment. These adverse drug reactions may 
range from mere troublesomeness to permanent 
disability or death [11,12]. 
 
Physicians are familiar with ADRs and they 
generally appreciate the importance of their role 
in reporting them. However, when it comes to 
whom to report ADRs; ADR responsible 
pharmacy staff and medication safety unit is 
neglected by physicians (however they were not 
mentioned explicitly in the provided response 
options but there was the “others” option) and 
majority of them didn’t recognize the hospital-
local or the national ADRs monitoring programs, 
this finding is similar to the finding of another 
study [11,13]. 
 
There is a general consensus among physicians 
that ADRs reporting is beneficial and should be 
mandatory. However, the role of pharmacists and 
the drug information center is minimized by 
physicians in favor of information technologies 
such as mobile applications or the internet and 
many of them were not familiar with ADRs alert 
forms provided in the wards, were disappointed 
by the information provided regarding ADRs and 
are not exactly sure whom to report these 
incidents to. 
 
There is also a lot of concern by physicians 
regarding possible legal consequences of 
reporting ADRs and some of them think that it’s a 
time consuming process. One study have 
suggested that physicians generally believe that 
reporting adverse drug events should be the 
responsibility of the nurse in charge [14] in 
addition to fears of loss of anonymity, another 
study cited the fear of blame as the main reason 
for not reporting especially amongst junior staff 
[15]. Many physicians expected feedback on 
their reports, in one study physicians along with 
nurses expressed that the provision of feedbacks 
on reports will likely encourage them to submit 
them [14]. 
 
The drug class with which physicians experience 
ADRs the most are antibiotics which are known 
to be amongst the most frequent medications 
associated with adverse drug events [16]. Almost 
half of physicians believe that reporting should 
be reserved only to serious reactions. 
 
The national pharmacovigilance program has 
only been established recently but it is expected 
to play a major role in the detection and 
prevention of adverse drug reactions and in order 
to achieve this goal it needs the participation of 
healthcare professionals like physicians who are 
in the frontline of patient care. However, limited 
number of studies has been done to assess the 
knowledge and perception of healthcare 
professionals toward ADRs reporting and more 
studies are needed in this regard. 
 
Limitations of the study 
 
The results of this study should be considered 
within the context of its limitations. Sampling was 
done using convenience sampling. Furthermore, 





The findings of this study highlight the important 
role of the medication safety unit and the local 
pharmacovigilance programs in hospital. 
Physicians need to be familiarized with the 
pharmacovigilance program and trained more in 
ADRs reporting process. This could be done via 
meetings, seminars and training sessions held by 
the medication safety unit for which participants 
could be awarded credit hours as an incentive. 
Also, regular check-ups of the alert forms stock 
in the nursing units are needed in order to 
encourage more ADRs reporting by physicians. 
More research is needed in various types of 
healthcare facilities involving a wide range of 
healthcare professionals to obtain a broader 
picture. 
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